Rgenta Therapeutics scores $20m seed

Cambridge, Massachusetts-based Rgenta Therapeutics, a developer of RNA-targeting medicines, has secured $20 million in seed funding.

Cambridge, Massachusetts-based Rgenta Therapeutics, a developer of RNA-targeting medicines, has secured $20 million in seed funding. Boehringer Ingelheim Venture Fund and Matrix Partners China led the round with participation from Kaitai Capital and Legend Star Fund.

Source: Press Release